Determining the Optimal Time Interval between Vaginal Dinoprostone Administration and Diagnostic Office Hysteroscopy in Nulliparous Women: A Randomized, Double-blind Trial.
Dinoprostone
Nulliparous women
Outpatient hysteroscopy
Pain
Journal
Journal of minimally invasive gynecology
ISSN: 1553-4669
Titre abrégé: J Minim Invasive Gynecol
Pays: United States
ID NLM: 101235322
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
05
03
2021
revised:
11
05
2021
accepted:
24
06
2021
pubmed:
5
7
2021
medline:
27
1
2022
entrez:
4
7
2021
Statut:
ppublish
Résumé
To determine the optimal timing of vaginal dinoprostone administration before office hysteroscopy (OH) in nulliparous women. Randomized, double-blind trial. Tertiary referral hospital. A total of 180 nulliparous women undergoing diagnostic OH. We randomly allocated the women to long-interval or short-interval dinoprostone groups: three mg dinoprostone was administered vaginally 12 hours before OH in the long-interval group and 3 hours before OH in the short-interval group. The primary outcome was pain during OH measured using a 100-mm visual analog scale (0 = no pain; 100 = worst pain imaginable). The secondary outcomes were ease of hysteroscope passage, patient satisfaction score, and drug-related adverse effects. The patients in the long-interval dinoprostone group had lower pain scores during OH (p <.001). Contrarily, pain scores 30 minutes after the procedure were similar in both groups (p = .1). The patient satisfaction score was higher and clinicians found hysteroscope passage through the cervical canal easier and quicker in the long-interval dinoprostone group than in the short-interval group (p <.001, p = .003, and p <.001, respectively). Side effects were comparable in both study groups. Vaginal dinoprostone administered 12 hours before OH was more effective than that administered 3 hours before OH in reducing pain during OH in nulliparous women, with easier hysteroscope insertion, shorter procedure duration, and higher patient satisfaction score.
Identifiants
pubmed: 34217851
pii: S1553-4650(21)00305-8
doi: 10.1016/j.jmig.2021.06.021
pii:
doi:
Substances chimiques
Oxytocics
0
Misoprostol
0E43V0BB57
Dinoprostone
K7Q1JQR04M
Banques de données
ClinicalTrials.gov
['NCT04085757']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
85-93Informations de copyright
Copyright © 2021. Published by Elsevier Inc.